Trial Profile

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Sacituzumab Tirumotecan (Primary)
Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Ductal carcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors Merck Sharp & Dohme

Most Recent Events

18 Jul 2025 Protocol has been amended. Timeframe of primary end point changed from 53 months to 63 months and planned patient number changed from 130 to 180 patients
18 Jul 2025 Planned number of patients changed from 130 to 180.
11 May 2025 Planned End Date changed from 3 Dec 2028 to 16 Oct 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com